Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant with or without anastrozole versus exemestane in ER-positive advanced or metastatic breast cancer after non-steroidal aromatase inhibitor progression
ISRCTN44195747Phase 3Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Fulvestrant plus placebo, Fulvestrant plus anastrozole and Exemestane (3 arms). Primary endpoint: Progression-free survival. Started Mar 2004; status: completed.
02
Drugs
fulvestrantanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN44195747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44195747.